Allison LaHood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Allison LaHood has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Carole D. Mitnick
Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA
4 shared publications - Molly Forrest Franke
Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA
4 shared publications - Letizia Trevisi
Department of Global Health and Social Medicine, Harvard Medical School
3 shared publications Michael L Rich
Division of Global Health Equity, Department of Medicine, Brigham and Women’s Hospital , Boston, MA
3 shared publicationsCarole D Mitnick
Department of Global Health and Social Medicine, Harvard Medical School. Boston, Massachusetts, USA. Partners In Health, Boston, Massachusetts, USA. Division of Global Health Equity, Department of Medicine, Brigham and Women’s Hospital Boston, Massachusetts
2 shared publications- Catherine Hewison
Medical Department, Médecins Sans Frontières, Paris, France
2 shared publications
Latest Publications
- Open Access
Clofazimine pharmacokinetics in novel rifampicin-resistant tuberculosis regimens: an analysis of the endTB and endTB-Q trials
Introduction: Rifampicin-resistant tuberculosis poses a significant threat worldwide. Clofazimine is considered important for the construction of effective individualized multidrug regimens to treat rifampicin-resistant tuberculosis. Our goal was to characterize clofazimine pharmacokinetics in novel combination treatment regimens and to identify participant characteristics associated with variations in drug exposure. Methods: Clofazimine pharmacokinetic data were obtained from adults and adolescents enrolled in the PandrTB pharmacokinetic sub-study of the endTB and endTB-Q Phase 3 randomized controlled therapeutic trials for rifampicin-resistant tuberculosis. Plasma concentrations were analyzed using nonlinear mixed-effects modeling to quantify clofazimine exposure and explore the impact of relevant covariates. Results: 100 participants from six countries with high burdens of rifampicin-resistant tuberculosis contributed pharmacokinetic data. Their median age was 34 years, 32% were female, 18% were living with diabetes mellitus, and 18% were living with HIV. Clofazimine plasma concentration values were best described by a 2-compartment pharmacokinetic model with first-order absorption. Co-administration with delamanid and HIV co-infection resulted in a 37% increase and 20% decrease in clofazimine’s bioavailability, respectively. Diabetes was associated with a 43% decrease in clofazimine clearance. Clofazimine remained in the body for a median of 2.5 years (95 th percentile: 0.5 – 8) following 9 months of treatment. Conclusion: Co-administration with delamanid, diabetes mellitus, and HIV were associated with variation in clofazimine exposure. We estimated that clofazimine remained present in the body for longer than two years in over half of participants following 9 months of treatment. Follow-up studies are recommended to confirm these associations before adjusting clofazimine dose or clinical care decisions.
Open AccessClofazimine pharmacokinetics in novel rifampicin-resistant tuberculosis regimens: an analysis of the endTB and endTB-Q trials
Introduction: Rifampicin-resistant tuberculosis poses a significant threat worldwide. Clofazimine is considered important for the construction of effective individualized multidrug regimens to treat rifampicin-resistant tuberculosis. Our goal was to characterize clofazimine pharmacokinetics in novel combination treatment regimens and to identify participant characteristics associated with variations in drug exposure. Methods: Clofazimine pharmacokinetic data were obtained from adults and adolescents enrolled in the PandrTB pharmacokinetic sub-study of the endTB and endTB-Q Phase 3 randomized controlled therapeutic trials for rifampicin-resistant tuberculosis. Plasma concentrations were analyzed using nonlinear mixed-effects modeling to quantify clofazimine exposure and explore the impact of relevant covariates. Results: 100 participants from six countries with high burdens of rifampicin-resistant tuberculosis contributed pharmacokinetic data. Their median age was 34 years, 32% were female, 18% were living with diabetes mellitus, and 18% were living with HIV. Clofazimine plasma concentration values were best described by a 2-compartment pharmacokinetic model with first-order absorption. Co-administration with delamanid and HIV co-infection resulted in a 37% increase and 20% decrease in clofazimine’s bioavailability, respectively. Diabetes was associated with a 43% decrease in clofazimine clearance. Clofazimine remained in the body for a median of 2.5 years (95 th percentile: 0.5 – 8) following 9 months of treatment. Conclusion: Co-administration with delamanid, diabetes mellitus, and HIV were associated with variation in clofazimine exposure. We estimated that clofazimine remained present in the body for longer than two years in over half of participants following 9 months of treatment. Follow-up studies are recommended to confirm these associations before adjusting clofazimine dose or clinical care decisions.
- Open Access
- 1 September 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (5) , dlag215
Promethazine use and QT prolongation risk during treatment with a shortened all-oral regimen for MDR/RR-TB
Background: Shortened all-oral regimens for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) combine multiple QTc prolonging agents, including bedaquiline and delamanid, which act partly through hERG potassium channel binding. Promethazine, a first-generation antihistamine used for nausea during TB therapy, shares this mechanism. Whether adjunctive promethazine further raises the risk of clinically relevant QTc prolongation in this setting is unclear. Methods: We conducted secondary analyses from a prospective observational cohort study of patients ≥15 years in Lesotho who received a 9- to 12-month all-oral regimen (bedaquiline, linezolid, levofloxacin, clofazimine, delamanid) for pulmonary MDR/RR-TB. We modelled time-varying promethazine exposure using the Andersen-Gill formulation of Cox regression, with time-to-first grade ≥3 (>500 ms) QTc event as the outcome of interest. We conducted comparator analyses with time-varying exposure to metoclopramide, ondansetron, and episodes of nausea, dizziness, and vomiting. Results: Among 247 participants (median age 41, 63.2% living with HIV), 62 (25.1%) received promethazine. Grade ≥3 QTc prolongation occurred in 10 (4.0%). Incident clinically significant QTc prolongation was higher during promethazine-exposed than unexposed periods (7.4 versus 1.3 per 10 000 person-days; HR 7.0, 95% CI: 1.4–35.3). No comparable elevation was seen in analyses of exposure to metoclopramide (HR 1.0, 95% CI: 0.3–3.6), ondansetron, or episodes of nausea, dizziness, or vomiting (HR 1.5, 95% CI: 0.3–6.9). Conclusions: Promethazine use was associated with increased risk of clinically relevant QTc prolongation within a QTc-burdened all-oral MDR/RR-TB regimen. These findings provide preliminary evidence that clinicians may consider when selecting anti-emetics as part of MDR/RR-TB therapy with a shortened all-oral regimen and highlight the importance of evaluating adjunctive medications in DR-TB care.
- 1 September 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (5) , dlag215
Open AccessPromethazine use and QT prolongation risk during treatment with a shortened all-oral regimen for MDR/RR-TB
Background: Shortened all-oral regimens for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) combine multiple QTc prolonging agents, including bedaquiline and delamanid, which act partly through hERG potassium channel binding. Promethazine, a first-generation antihistamine used for nausea during TB therapy, shares this mechanism. Whether adjunctive promethazine further raises the risk of clinically relevant QTc prolongation in this setting is unclear. Methods: We conducted secondary analyses from a prospective observational cohort study of patients ≥15 years in Lesotho who received a 9- to 12-month all-oral regimen (bedaquiline, linezolid, levofloxacin, clofazimine, delamanid) for pulmonary MDR/RR-TB. We modelled time-varying promethazine exposure using the Andersen-Gill formulation of Cox regression, with time-to-first grade ≥3 (>500 ms) QTc event as the outcome of interest. We conducted comparator analyses with time-varying exposure to metoclopramide, ondansetron, and episodes of nausea, dizziness, and vomiting. Results: Among 247 participants (median age 41, 63.2% living with HIV), 62 (25.1%) received promethazine. Grade ≥3 QTc prolongation occurred in 10 (4.0%). Incident clinically significant QTc prolongation was higher during promethazine-exposed than unexposed periods (7.4 versus 1.3 per 10 000 person-days; HR 7.0, 95% CI: 1.4–35.3). No comparable elevation was seen in analyses of exposure to metoclopramide (HR 1.0, 95% CI: 0.3–3.6), ondansetron, or episodes of nausea, dizziness, or vomiting (HR 1.5, 95% CI: 0.3–6.9). Conclusions: Promethazine use was associated with increased risk of clinically relevant QTc prolongation within a QTc-burdened all-oral MDR/RR-TB regimen. These findings provide preliminary evidence that clinicians may consider when selecting anti-emetics as part of MDR/RR-TB therapy with a shortened all-oral regimen and highlight the importance of evaluating adjunctive medications in DR-TB care.
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Low Post-Treatment Recurrence After a Shortened All-oral Regimen for Pulmonary Rifampicin- or Multidrug-Resistant Tuberculosis in Individuals without Prior Second-Line Drug Exposure in Kazakhstan
We conducted a prospective cohort study of adults with pulmonary MDR/RR-TB in Kazakhstan treated with one of three all-oral, five-drug regimens. Individuals were followed microbiologically and clinically for up to 12 months post-treatment. Of 578 with favorable end-of-treatment outcomes, we observed only one incident case of recurrent TB (0.2%, 95%CI: 0.0-1.0%), suggesting excellent regimen durability under programmatic conditions.
- 1 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessLow Post-Treatment Recurrence After a Shortened All-oral Regimen for Pulmonary Rifampicin- or Multidrug-Resistant Tuberculosis in Individuals without Prior Second-Line Drug Exposure in Kazakhstan
We conducted a prospective cohort study of adults with pulmonary MDR/RR-TB in Kazakhstan treated with one of three all-oral, five-drug regimens. Individuals were followed microbiologically and clinically for up to 12 months post-treatment. Of 578 with favorable end-of-treatment outcomes, we observed only one incident case of recurrent TB (0.2%, 95%CI: 0.0-1.0%), suggesting excellent regimen durability under programmatic conditions.
- Open Access
- 12 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation
Background: Peripheral neuropathy frequently leads to linezolid dose reductions or interruptions during multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. The implications of these modifications on treatment success are uncertain. Methods: We conducted a target trial emulation using the endTB Observational Study among individuals who developed non-severe peripheral neuropathy while receiving linezolid 600 mg daily within 6 months of initiating an individualized MDR/RR-TB regimen. We examined three linezolid management strategies: immediate change (i.e., dose reduction, temporary interruption, discontinuation) within Weeks 1–7 after peripheral neuropathy onset, deferred change within Weeks 8–26, and no change (i.e., continuing linezolid 600 mg daily) during Weeks 1–26. To emulate the per-protocol analysis of a trial, we used an approach involving cloning and censoring participant data, and applying inverse probability of censoring weights. Results: Among 303 eligible participants from 12 countries, peripheral neuropathy occurred a median of 11 weeks (interquartile range: 4–18) after treatment initiation. Weighted, standardized probabilities of treatment success were 84.7% (95% CI: 69.2%, 92.9%) for immediate change, 78.9% (95% CI: 65.9%, 87.1%) for deferred change, and 85.2% (95% CI: 80.5%, 89.1%) for no change. Compared with no change, treatment success ratios were 0.99 (95% CI: 0.83, 1.11) for immediate change and 0.93 (95% CI: 0.78, 1.01) for deferred change. Conclusions: We did not find evidence of a substantial negative impact of immediate modification to linezolid on MDR/RR-TB treatment success. Our results support the clinical practice of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy.
- 12 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessComparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation
Background: Peripheral neuropathy frequently leads to linezolid dose reductions or interruptions during multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. The implications of these modifications on treatment success are uncertain. Methods: We conducted a target trial emulation using the endTB Observational Study among individuals who developed non-severe peripheral neuropathy while receiving linezolid 600 mg daily within 6 months of initiating an individualized MDR/RR-TB regimen. We examined three linezolid management strategies: immediate change (i.e., dose reduction, temporary interruption, discontinuation) within Weeks 1–7 after peripheral neuropathy onset, deferred change within Weeks 8–26, and no change (i.e., continuing linezolid 600 mg daily) during Weeks 1–26. To emulate the per-protocol analysis of a trial, we used an approach involving cloning and censoring participant data, and applying inverse probability of censoring weights. Results: Among 303 eligible participants from 12 countries, peripheral neuropathy occurred a median of 11 weeks (interquartile range: 4–18) after treatment initiation. Weighted, standardized probabilities of treatment success were 84.7% (95% CI: 69.2%, 92.9%) for immediate change, 78.9% (95% CI: 65.9%, 87.1%) for deferred change, and 85.2% (95% CI: 80.5%, 89.1%) for no change. Compared with no change, treatment success ratios were 0.99 (95% CI: 0.83, 1.11) for immediate change and 0.93 (95% CI: 0.78, 1.01) for deferred change. Conclusions: We did not find evidence of a substantial negative impact of immediate modification to linezolid on MDR/RR-TB treatment success. Our results support the clinical practice of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy.
- Open Access
- 2 February 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (6) , 1615-1623
Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence
Hepatitis C virus (HCV) infection is associated with unfavorable multidrug- and rifampicin-resistant (MDR/RR) tuberculosis (TB) outcomes. We examined whether this association would decrease in settings where no participants were lost-to-follow-up or where all adhered to regimens comprised of priority TB drugs. We analyzed data from 1,530 participants with HCV testing in the endTB observational cohort (NCT03259269). We estimated the relative risk of death, treatment failure, and loss-to-follow-up comparing participants with and without HCV, using inverse probability weighting to adjust for confounding. We then estimated relative risks of HCV on death and failure in weighted pseudopopulations representing hypothetical interventions eliminating loss-to-follow-up and ensuring adherence to strong MDR/RR-TB regimens. The unadjusted risk difference comparing participants with and without HCV was 14.1% (95% confidence interval [CI], 8.0%-20.1%), decreasing to 11.0% (95% CI, 3.0%-19.1%) after weighting. In pseudopopulations without loss-to-follow-up or with adequate adherence to strong regimens, the risk differences were 7.7% (95% CI, 0.8%-16.2%) and 7.0% (95% CI,−1.6% to 17.3%), respectively. Adjustment for baseline confounders attenuated the association between HCV and unfavorable outcomes, suggesting these factors partly explain the disparity. Further attenuation after eliminating loss-to-follow-up suggests that improving treatment retention in MDR/RR-TB care may reduce outcome disparities among patients with HCV.
- 2 February 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (6) , 1615-1623
Open AccessEstimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence
Hepatitis C virus (HCV) infection is associated with unfavorable multidrug- and rifampicin-resistant (MDR/RR) tuberculosis (TB) outcomes. We examined whether this association would decrease in settings where no participants were lost-to-follow-up or where all adhered to regimens comprised of priority TB drugs. We analyzed data from 1,530 participants with HCV testing in the endTB observational cohort (NCT03259269). We estimated the relative risk of death, treatment failure, and loss-to-follow-up comparing participants with and without HCV, using inverse probability weighting to adjust for confounding. We then estimated relative risks of HCV on death and failure in weighted pseudopopulations representing hypothetical interventions eliminating loss-to-follow-up and ensuring adherence to strong MDR/RR-TB regimens. The unadjusted risk difference comparing participants with and without HCV was 14.1% (95% confidence interval [CI], 8.0%-20.1%), decreasing to 11.0% (95% CI, 3.0%-19.1%) after weighting. In pseudopopulations without loss-to-follow-up or with adequate adherence to strong regimens, the risk differences were 7.7% (95% CI, 0.8%-16.2%) and 7.0% (95% CI,−1.6% to 17.3%), respectively. Adjustment for baseline confounders attenuated the association between HCV and unfavorable outcomes, suggesting these factors partly explain the disparity. Further attenuation after eliminating loss-to-follow-up suggests that improving treatment retention in MDR/RR-TB care may reduce outcome disparities among patients with HCV.
- Open Access
- 20 January 2026
- Published by Elsevier in SSRN Electronic Journal
5-Year Effectiveness of An Oral Cholera Vaccine in a Cholera Outbreak in Rural Haiti: A Case-Control Study
Background: The World Health Organization recommends use of killed oral cholera vaccines (kOCV) as part of cholera prevention and control, but data on the duration of effectiveness of the most widely available vaccine, Euvichol® is limited. We evaluated the effectiveness of Euvichol® 5 years after a kOCV campaign conducted in Haiti in 2017.Methods: We undertook a frequency-matched case-control study in Mirebalais, Haiti from October 2022 to February 2023 as a cholera outbreak resurged. Cases were patients with acute watery diarrhea, had a stool sample positive for V. cholerae by polymerase chain reaction, and had been eligible for kOCV during the 2017 campaign. Cases were frequency-matched with community controls by age group and neighborhood. Participants reported sociodemographics, risk factors, and vaccination status. We used adjusted logistic regression analyses to estimate vaccine effectiveness (VE) of at least one kOCV dose versus none.Findings: We analyzed 93 cases and 135 controls. 22% of the cases and 51% of the controls self-reported vaccination. Receiving Euvichol in 2017 was associated with a 5-year adjusted VE of 78% (95% CI: 57%-89%, p<0.0001).Interpretation: Euvichol® effectively protected against cholera in Haiti, 5 years after a vaccination campaign. This has important implications for public health planning, especially consideration of re-dosing schedules and comparative effectiveness analyses.
- 20 January 2026
- Published by Elsevier in SSRN Electronic Journal
Open Access5-Year Effectiveness of An Oral Cholera Vaccine in a Cholera Outbreak in Rural Haiti: A Case-Control Study
Background: The World Health Organization recommends use of killed oral cholera vaccines (kOCV) as part of cholera prevention and control, but data on the duration of effectiveness of the most widely available vaccine, Euvichol® is limited. We evaluated the effectiveness of Euvichol® 5 years after a kOCV campaign conducted in Haiti in 2017.Methods: We undertook a frequency-matched case-control study in Mirebalais, Haiti from October 2022 to February 2023 as a cholera outbreak resurged. Cases were patients with acute watery diarrhea, had a stool sample positive for V. cholerae by polymerase chain reaction, and had been eligible for kOCV during the 2017 campaign. Cases were frequency-matched with community controls by age group and neighborhood. Participants reported sociodemographics, risk factors, and vaccination status. We used adjusted logistic regression analyses to estimate vaccine effectiveness (VE) of at least one kOCV dose versus none.Findings: We analyzed 93 cases and 135 controls. 22% of the cases and 51% of the controls self-reported vaccination. Receiving Euvichol in 2017 was associated with a 5-year adjusted VE of 78% (95% CI: 57%-89%, p<0.0001).Interpretation: Euvichol® effectively protected against cholera in Haiti, 5 years after a vaccination campaign. This has important implications for public health planning, especially consideration of re-dosing schedules and comparative effectiveness analyses.
- Open Access
- 25 July 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (7) , e0271102
Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different
Background: Tuberculosis (TB), human immunodeficiency virus (HIV), and hepatitis C virus (HCV) share a global presence and propensity to disproportionately affect marginalized populations. However, over recent decades, many fewer drugs have been brought to market for TB than for the others. Although three new anti-TB drugs have been approved in the US or Europe in the last 10 years, uptake of these drugs has been limited. Using case examples of drugs developed recently for TB, HIV, and HCV, we explore possible reasons. We examine the use and effect of regulatory pathways intended to address weak economic incentives in the face of urgent, unmet needs; evaluate the extent of data underpinning authorizations for these indications; document development timelines and evidence available at the time of each approval; consider explanations for observed differences; and discuss the implications for clinical guidelines and use. Methods and findings: For each indication, we selected two drugs: one recently approved and one approved between 2012 and 2014, when the first new anti-TB drug from a novel class in more than 40 years received marketing authorization. We calculated time from first published peer-reviewed evidence of activity to date of approval; the number of phase 1, 2, and 3 trials; the number of trial participants randomized to treatment arms containing the drug; and the total number of participants in each trial from the individual drug approval packages. We found that the two TB drugs took longer to gain approval (8.0 and 19.2 years for bedaquiline and pretomanid, respectively) despite availing of special regulatory pathways meant to expedite approval, when compared to the HIV (2.6 years for dolutegravir and 4.7 years for doravirine) and HCV drugs (3.2 and 1.6 years for sofosbuvir and glecaprevir/pibrentasvir, respectively). Moreover, fewer participants were studied prior to TB drug approvals (380 and 879) than prior to approvals for HIV (1598 and 979) and for HCV (2291 and 2448) drugs. Conclusions: The dramatic disparities observed in TB drug development reaffirm the importance of several actions. Increased investment in TB research and development is necessary to rapidly advance drugs through the pipeline. Development plans and partnerships must provide safety and efficacy evidence on combinations and durations that are relevant to real-world use in heterogeneous populations. Reliable, validated surrogate markers of relapse-free cure are essential to decrease the duration and cost of TB treatment trials and increase the confidence and speed with which new regimens can advance. Lastly, regulators and normative bodies must maintain high evidentiary standards for authorization while ensuring timely and broad approval for TB drugs and regimens.
- 25 July 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (7) , e0271102
Open AccessComparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different
Background: Tuberculosis (TB), human immunodeficiency virus (HIV), and hepatitis C virus (HCV) share a global presence and propensity to disproportionately affect marginalized populations. However, over recent decades, many fewer drugs have been brought to market for TB than for the others. Although three new anti-TB drugs have been approved in the US or Europe in the last 10 years, uptake of these drugs has been limited. Using case examples of drugs developed recently for TB, HIV, and HCV, we explore possible reasons. We examine the use and effect of regulatory pathways intended to address weak economic incentives in the face of urgent, unmet needs; evaluate the extent of data underpinning authorizations for these indications; document development timelines and evidence available at the time of each approval; consider explanations for observed differences; and discuss the implications for clinical guidelines and use. Methods and findings: For each indication, we selected two drugs: one recently approved and one approved between 2012 and 2014, when the first new anti-TB drug from a novel class in more than 40 years received marketing authorization. We calculated time from first published peer-reviewed evidence of activity to date of approval; the number of phase 1, 2, and 3 trials; the number of trial participants randomized to treatment arms containing the drug; and the total number of participants in each trial from the individual drug approval packages. We found that the two TB drugs took longer to gain approval (8.0 and 19.2 years for bedaquiline and pretomanid, respectively) despite availing of special regulatory pathways meant to expedite approval, when compared to the HIV (2.6 years for dolutegravir and 4.7 years for doravirine) and HCV drugs (3.2 and 1.6 years for sofosbuvir and glecaprevir/pibrentasvir, respectively). Moreover, fewer participants were studied prior to TB drug approvals (380 and 879) than prior to approvals for HIV (1598 and 979) and for HCV (2291 and 2448) drugs. Conclusions: The dramatic disparities observed in TB drug development reaffirm the importance of several actions. Increased investment in TB research and development is necessary to rapidly advance drugs through the pipeline. Development plans and partnerships must provide safety and efficacy evidence on combinations and durations that are relevant to real-world use in heterogeneous populations. Reliable, validated surrogate markers of relapse-free cure are essential to decrease the duration and cost of TB treatment trials and increase the confidence and speed with which new regimens can advance. Lastly, regulators and normative bodies must maintain high evidentiary standards for authorization while ensuring timely and broad approval for TB drugs and regimens.